Advertisement
Research Article

MyD88 Is Required for Protection from Lethal Infection with a Mouse-Adapted SARS-CoV

  • Timothy Sheahan equal contributor,

    equal contributor Contributed equally to this work with: Timothy Sheahan, Thomas E. Morrison

    Affiliations: Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

    X
  • Thomas E. Morrison equal contributor,

    equal contributor Contributed equally to this work with: Timothy Sheahan, Thomas E. Morrison

    Affiliations: Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, Carolina Vaccine Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

    X
  • William Funkhouser,

    Affiliation: Department of Pathology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America

    X
  • Satoshi Uematsu,

    Affiliation: WPI Immunology Frontier Research Center, Laboratory of Host Defense, Osaka University, Suita, Osaka, Japan

    X
  • Shizou Akira,

    Affiliation: WPI Immunology Frontier Research Center, Laboratory of Host Defense, Osaka University, Suita, Osaka, Japan

    X
  • Ralph S. Baric mail,

    rbaric@email.unc.edu (RSB); heisem@med.unc.edu (MTH)

    Affiliations: Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

    X
  • Mark T. Heise mail

    rbaric@email.unc.edu (RSB); heisem@med.unc.edu (MTH)

    Affiliations: Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, Carolina Vaccine Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

    X
  • Published: December 12, 2008
  • DOI: 10.1371/journal.ppat.1000240

About the Authors

Timothy Sheahan, Ralph S. Baric, Mark T. Heise
Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
Timothy Sheahan, Ralph S. Baric
Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
Thomas E. Morrison, Mark T. Heise
Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
Thomas E. Morrison, Mark T. Heise
Carolina Vaccine Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
William Funkhouser
Department of Pathology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America
Satoshi Uematsu, Shizou Akira
WPI Immunology Frontier Research Center, Laboratory of Host Defense, Osaka University, Suita, Osaka, Japan

Corresponding Authors

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: TS TEM RSB MTH. Performed the experiments: TS TEM. Analyzed the data: TS TEM WF. Contributed reagents/materials/analysis tools: SU SA. Wrote the paper: TS TEM WF RSB MTH.